Radioimmunotherapy-based treatment of cancer
Authors
Abstract:
The principle of cancer immunotherapy includes various methods of manipulations to influence immune responses against tumors in both humans and animals. This advanced technology of hybridoma production provided the necessary skills to efficiently produce highly specific monoclonal antibodies (mAb). Radioactively-tagged antibodies which are applied in radioimmunotherapy (RIT), can target adjacent cells and may not require immune function. This study highlights the mechanism and the effect of action of radioimmunotherapic agents, especially two applied agents including 90Y-ibritumomab tiuxetan and 131I-tositumomab that are approved by Food and Drug Administration (FDA) for treatment of some cancers.
similar resources
radioimmunotherapy-based treatment of cancer
the principle of cancer immunotherapy includes various methods of manipulations to influence immune responses against tumors in both humans and animals. this advanced technology of hybridoma production provided the necessary skills to efficiently produce highly specific monoclonal antibodies (mab). radioactively-tagged antibodies which are applied in radioimmunotherapy (rit), can target adjacen...
full textPretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer
Medullary thyroid carcinoma (mtc) is a rare cancer (less than 8% of all thyroid cancers) that occurs both as a familial and as a sporadic disease. Total thyroidectomy with dissection of the ipsilateral and central lymph nodes, sometimes extended to contralateral dissection, is the primary treatment of hereditary and sporadic mtc alike. after surgery, many patients are cured, especially those wi...
full textRadioimmunotherapy for colorectal cancer.
Monoclonal antibodies, selected for their ability to recognize and bind tumor-specific antigens, are a promising vehicle for systemic antitumor therapy. Radioimmunotherapy utilizes radioisotopes conjugated to monoclonal antibodies to deliver tumoricidal radiation doses. In the >20 years since radioimmunotherapy began, many obstacles to successful application of this antitumor modality have been...
full textIntraperitoneal radioimmunotherapy for ovarian cancer.
Twenty-eight patients with assessable residual ovarian cancer after cytoreductive surgery and chemotherapy received intraperitoneal I-131 labelled monoclonal antibodies. There was no response in eight patients with tumour nodules greater than 2 cm, a partial response in two of the 15 patients with tumour nodules less than 2 cm, and a complete response in three of the other five patients with po...
full textMy Resources
Journal title
volume 20 issue 1
pages 45- 53
publication date 2012-12-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023